These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
250 related articles for article (PubMed ID: 31108244)
1. High-dose interleukin-2 and interferon as first-line immunotherapy for metastatic melanoma: long-term follow-up in a large unselected Danish patient cohort. Bastholt L; Svane IM; Bjerregaard JK; Herrstedt J; Hróbjartsson A; Schmidt H Eur J Cancer; 2019 Jul; 115():61-67. PubMed ID: 31108244 [TBL] [Abstract][Full Text] [Related]
2. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. McQuade JL; Daniel CR; Hess KR; Mak C; Wang DY; Rai RR; Park JJ; Haydu LE; Spencer C; Wongchenko M; Lane S; Lee DY; Kaper M; McKean M; Beckermann KE; Rubinstein SM; Rooney I; Musib L; Budha N; Hsu J; Nowicki TS; Avila A; Haas T; Puligandla M; Lee S; Fang S; Wargo JA; Gershenwald JE; Lee JE; Hwu P; Chapman PB; Sosman JA; Schadendorf D; Grob JJ; Flaherty KT; Walker D; Yan Y; McKenna E; Legos JJ; Carlino MS; Ribas A; Kirkwood JM; Long GV; Johnson DB; Menzies AM; Davies MA Lancet Oncol; 2018 Mar; 19(3):310-322. PubMed ID: 29449192 [TBL] [Abstract][Full Text] [Related]
3. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a]. Kirchner HH; Atzpodien J; Poliwoda H Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119 [TBL] [Abstract][Full Text] [Related]
4. Effect of interferon-α-2b and interleukin-2 combined with chemotherapy in metastatic melanoma. Su Z; Shi F; Zhang J; Liang W Panminerva Med; 2024 Jun; 66(2):131-136. PubMed ID: 32700883 [TBL] [Abstract][Full Text] [Related]
5. Randomized trial of treatment with cisplatin and interleukin-2 either alone or in combination with interferon-alpha-2a in patients with metastatic melanoma: a Federation Nationale des Centres de Lutte Contre le Cancer Multicenter, parallel study. Dorval T; Négrier S; Chevreau C; Avril MF; Baume D; Cupissol D; Oskam R; de Peuter R; Vinke J; Herrera A; Escudier B Cancer; 1999 Mar; 85(5):1060-6. PubMed ID: 10091789 [TBL] [Abstract][Full Text] [Related]
11. Systemic therapy for unresectable metastatic melanoma: impact of biochemotherapy on long-term survival. Bedikian AY; Johnson MM; Warneke CL; McIntyre S; Papadopoulos N; Hwu WJ; Kim K; Hwu P J Immunotoxicol; 2008 Apr; 5(2):201-7. PubMed ID: 18569391 [TBL] [Abstract][Full Text] [Related]
12. A phase II study of outpatient subcutaneous histamine dihydrochloride, interleukin-2 and interferon-alpha in patients with metastatic melanoma. Schmidt H; Larsen S; Bastholt L; Fode K; Rytter C; Von Der Maase H Ann Oncol; 2002 Dec; 13(12):1919-24. PubMed ID: 12453861 [TBL] [Abstract][Full Text] [Related]
13. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, intravenous combination chemotherapy, and oral tamoxifen in the treatment of metastatic melanoma: final results of cancer biotherapy research group 94-11. Dillman RO; Soori G; Wiemann MC; Schulof R; Dobbs TW; Ruben RH; DePriest CB; Church C Cancer Biother Radiopharm; 2000 Oct; 15(5):487-94. PubMed ID: 11155820 [TBL] [Abstract][Full Text] [Related]
14. ECOG phase II trial of graded-dose peginterferon α-2b in patients with metastatic melanoma overexpressing basic fibroblast growth factor (E2602). Go RS; Lee SJ; Shin D; Callister SM; Jobe DA; Conry RM; Tarhini AA; Kirkwood JM Clin Cancer Res; 2013 Dec; 19(23):6597-604. PubMed ID: 24122792 [TBL] [Abstract][Full Text] [Related]
15. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial. Larkin J; Minor D; D'Angelo S; Neyns B; Smylie M; Miller WH; Gutzmer R; Linette G; Chmielowski B; Lao CD; Lorigan P; Grossmann K; Hassel JC; Sznol M; Daud A; Sosman J; Khushalani N; Schadendorf D; Hoeller C; Walker D; Kong G; Horak C; Weber J J Clin Oncol; 2018 Feb; 36(4):383-390. PubMed ID: 28671856 [TBL] [Abstract][Full Text] [Related]
16. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab. Muto Y; Kitano S; Tsutsumida A; Namikawa K; Takahashi A; Nakamura Y; Yamanaka T; Yamamoto N; Yamazaki N J Dermatol; 2019 Jun; 46(6):498-506. PubMed ID: 30945333 [TBL] [Abstract][Full Text] [Related]
17. A randomized phase II trial of interleukin-2 and interferon-α plus bevacizumab versus interleukin-2 and interferon-α in metastatic renal-cell carcinoma (mRCC): results from the Danish Renal Cancer Group (DaRenCa) study-1. Donskov F; Jensen NV; Smidt-Hansen T; Brøndum L; Geertsen P Acta Oncol; 2018 May; 57(5):589-594. PubMed ID: 29392960 [TBL] [Abstract][Full Text] [Related]
18. Treatment of metastatic melanoma with combined chemotherapy containing cisplatin, vinblastine and dacarbazine (CVD) and biotherapy using interleukin-2 and interferon-alpha. Legha SS; Ring S; Bedikian A; Plager C; Eton O; Buzaid AC; Papadopoulos N Ann Oncol; 1996 Oct; 7(8):827-35. PubMed ID: 8922197 [TBL] [Abstract][Full Text] [Related]